• SyncroPatch 384/768i

    全球最高通量的全自动膜片钳系统
  • SyncroPatch 384/768i

    平行记录384个细胞 => 最高可升级到768个
  • SyncroPatch 384/768i

    真正的高通量与GΩ级封接
  • SyncroPatch 384/768i

    Analysis Software even more powerful than before
  • SyncroPatch 384/768i

    高科技保证实验的灵活性

2019 - Design, synthesis and characterization of novel N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors leading to the identification of the selective compound, AC1903

icon sp96   SyncroPatch 384PE article in Bioorganic and Medicinal Chemistry Letters (2019)

Authors:
Sharma, S.H., Pablo J.L., Montesinos, M.S., Greka, A., Hopkins, C.R.

Journal:
Bioorganic and Medicinal Chemistry Letters (2019) 29(2): 155-159


Abstract:

The transient receptor potential cation channel 5 (TRPC5) has been previously shown to affect podocyte survival in the kidney. As such, inhibitors of TRPC5 are interesting candidates for the treatment of chronic kidney disease (CKD). Herein, we report the synthesis and biological characterization of a series of N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors. Work reported here evaluates the benzimidazole scaffold and substituents resulting in the discovery of AC1903, a TRPC5 inhibitor that is active in multiple animal models of CKD.


Download here

返回总览

SyncroPatch 384i brochure

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.